Leica Microsystems

Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.

Leica Biosystems aims to create a companion test for seribantumab, an investigational human monoclonal antibody used in combination therapy to treat cancer.

The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.

Affymetrix this week reported a slight uptick in its second-quarter revenues, which increased 3 percent to $66.4 million from $64.7 million in the year-ago period, beating the average analyst estimate of $65.6 million.

NEW YORK (GenomeWeb News) – Affymetrix and Leica Microsystems today announced a deal to automate Affymetrix's QuantiGene View RNA ISH Tissue Assay on the Leica Bond RX staining platform for research applications.

BG Medicine this week appointed Eric Bouvier as president and CEO. He replaces Pieter Muntendam, who has moved to the role of executive vice president and chief medical officer.

The alliance will combine Leica's automated confocal instruments with Definiens' analysis software.

Abbott's PathVysion FISH assay will be used to develop the test on Leica's BOND platform.

Genetix will operate as a separate business unit within Danaher subsidiary Leica Microsystems.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.